Together, this set of experiments reveals a novel cooperation of PLK1 inhibition and microtubule-targeting drugs like paclitaxel to reduce cell viability in ovarian cancer cell lines with CCNE1-amplification. The gene discussed is PLK1; the disease is ovarian carcinoma.